Poster - Technology Transferhttp://ncifrederick.cancer.gov/about/theposter/tags/technology-transfer
enSuccess of Breast Cancer Startup Challenge Inspires Second Challengehttp://ncifrederick.cancer.gov/about/theposter/content/success-breast-cancer-startup-challenge-inspires-second-challenge
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/NeuroStartUpLogo_Color_480x310.jpg?itok=Aly8PSk5"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/NeuroStartUpLogo_Color_480x310.jpg?itok=Aly8PSk5" width="480" height="310" alt="The neuro Start Up Challenge logo" /></figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Thomas Stackhouse, Joseph Conrad, and Michele Newton, Contributing Writers, and Rosemarie Truman, Guest Writer</em></p>
<p>Sixty-one teams have been accepted into, and are now competing in, the <a href="http://www.neurostartupchallenge.org/">Neuro Startup Challenge</a>, a new collaboration established by the <a href="http://www.nih.gov/">National Institutes of Health</a> (NIH) with The <a href="http://www.thecenterforadvancinginnovation.org/">Center for Advancing Innovation</a> (CAI) and <a href="http://www.heritageprovidernetwork.com/">Heritage Provider Network</a>, Inc.</p>
<p>The Neuro Startup Challenge is the second of its kind and is modeled after the <a href="http://www.breastcancerstartupchallenge.com/">Breast Cancer Startup Challenge</a> (BCSC), which was conceived through a partnership between NCI, CAI, and the Avon Foundation for Women to accelerate the process of bringing emerging breast cancer technologies to market and to stimulate the creation of start-up businesses around the inventions. </p>
<p><strong>The Breast Cancer Startup Challenge Established the Model</strong></p>
<p>The BCSC, established in 2013, comprised nine patented technologies from NCI and one from an Avon-funded research facility that were judged as having great promise for advancing breast cancer research in addition to being appropriate for startups. Teams of business, legal, medical/scientific, and engineering specialists, computer science students, seasoned entrepreneurs, and other industry professionals competed by creating business plans, giving live sales pitches, and making <a href="https://www.youtube.com/user/BCStartupChallenge">elevator speeches</a> focused on developing and commercializing the inventions.</p>
<p>In March 2014, the challenge winners and finalists launched their startups, and began to raise funds and negotiate a license for their inventions. As a result of the BCSC, more than 270 challenge competitors received start-up and entrepreneurship training, 10 breast cancer–related inventions are being advanced, and 11 startups have been launched.</p>
<p>Three of the start-up companies that have been granted exclusive licenses to the NCI technology include Mesopharm (Mitchell Ho, Ph.D., Laboratory of Molecular Biology, NCI Center for Cancer Research [CCR], inventor, Human Monoclonal Antibody–Based Cancer Therapy); Orpheden (Alan Krensky, M.D., formerly NCI, inventor, Immunotherapy Using Granulysin-Activated Monocytes); and Oncolinx (Nadya Tarasova, Ph.D., Cancer and Inflammation Program, NCI CCR, inventor, Anti-Cancer Toxin).</p>
<p>In November 2014, the BCSC was awarded with an Excellence in Technology Transfer Award from the Federal Laboratory Consortium for Technology Transfer (FLC) Mid-Atlantic Region. In July 2014, the new secretary of the U.S. Department of Health and Human Services (HHS), Sylvia Burwell, recognized the BCSC with a Secretary’s Pick Award in the HHS Innovates competition, which celebrates inventive new ideas in support of the HHS mission.</p>
<p><strong>The Neuro Startup Challenge Expands the Model</strong></p>
<p>Given its promising initial results, the BCSC template is now being applied systematically as a model for advancing NIH-licensable technologies and helping to create start-up companies. <a href="http://www.neurostartupchallenge.org/">The Neuro Startup Challenge</a>, which centers around 16 unlicensed brain-related inventions from multiple NIH institutes, was launched using an enhanced version of the BCSC framework.</p>
<p>In this new challenge, 61 teams comprising graduate-level medical and business students and postdocs, as well as seasoned entrepreneurs, will compete to create strategic business plans and launch startups to develop and commercialize the inventions.</p>
<p><strong>NCI Technologies Competing in the New Challenge</strong></p>
<p>NCI technologies that have been accepted into the Neuro Startup Challenge include: A Brain Cancer–Specific Target That Can Be Used in Diagnostics and Potentially Therapeutic Applications (Zheng-Gang Liu, Ph.D., Laboratory of Genitourinary Cancer Pathogenesis, NCI CCR, inventor); A Tumor Diagnostic Marker for New Blood Vessels’ Formation That Can Be Used for Early Detection of Brain Tumors (Brad St. Croix, Ph.D, Mouse Cancer Genetics Program, NCI CCR, inventor); and InvNovel Synthetic Analogues of Schweinfurthin A for the Treatment of Neurofibromatosis Type 1 (Karlyne Reilly, Ph.D., Genetic Modifiers of Tumorigenesis Section, NCI CCR, and John Beutler, Ph.D., Molecular Targets Laboratory, NCI CCR, inventors).</p>
<p>CAI is continuing its partnership role in this new challenge, and Heritage Provider Network is engaged as a philanthropic partner.</p>
<p><strong>Challenge Platform Offers Many Advantages</strong></p>
<p>According to the Core Challenge Planning Team from the Technology Transfer Center, NCI at Frederick, and CAI, the challenge platform offers a number of significant advantages to advancing technology, including:</p>
<ul><li>Creating a new model to help accelerate and simultaneously transfer multiple federal inventions to the marketplace where they can have an opportunity to positively impact public health</li>
<li>Establishing a collaboration between the best minds and ideas from the federal, private, academic, and entrepreneurial arenas to accomplish a common goal</li>
<li>Creating a competition whose outcome has the potential to stimulate economic growth and create jobs</li>
<li>Providing an excellent platform to help postdocs and graduate students learn “the business of science” </li>
<li>Providing an opportunity to help train and motivate the next generation to meet our agency’s mission, which, in this case, involves the training of scientists and entrepreneurs who will take us to the next milestones in NCI’s journey to improve life for those who suffer from cancer</li>
<li>Providing a new model for venture philanthropy – Avon viewed the challenge as an opportunity to strategically invest in, and offer support to, a program with the potential to advance multiple breast cancer–related inventions</li>
</ul><p>The Neuro Startup Challenge provides the opportunity to help accelerate and increase the volume of advancements for brain-related health concerns by building on the unique framework created with the BCSC. The challenge concept is designed to serve as a model for institutionalizing the practice of spinning off inventions across HHS and other federal labs.</p>
<p>For more information, please visit the <a href="http://www.neurostartupchallenge.org/">Neuro Startup Challenge</a> or the <a href="http://www.breastcancerstartupchallenge.com/">Breast Cancer Startup Challenge</a> website.</p>
<p><em>Rosemarie Truman is founder and chief executive officer, Center for Advancing Innovation.</em></p>
<p><em><img alt="" src="/about/theposter/sites/default/files/Startup-480x286.jpg" style="float:left; height:477px; margin:10px; width:800px" /></em></p>
<p><span style="font-size:12px">The Breast Cancer Startup Challenge was recognized with a Secretary’s Pick Award at the HHS Innovates Award Ceremony in July 2014. From left: Thomas Stackhouse, Ph.D., associate director, NCI Technology Transfer Center (TTC); Karen Maurey, director, NCI TTC; Animesh Shukla, CAI; Rosemarie Truman, founder and CEO, CAI; Jonathan Liu, CAI; Li Gwatkin, NCI Office of Communications; Bill Corr, deputy secretary, HHS; Sylvia Burwell, secretary of HHS; James Anderson, M.D., Ph.D., director, NIH Division of Program Coordination, Planning, and Strategic Initiatives; Jennifer Wong, technology licensing specialist, NIH Office of Technology Transfer (OTT); Michele Newton, marketing specialist, NCI TTC; Youhong Wang, CAI; Richard Rodriguez, director, NIH OTT; and John Hewes, Ph.D., technology transfer specialist, NCI TTC. Photo courtesy of Christopher Smith, ASPA.</span></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2015-january" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2015 January</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Fri, 30 Jan 2015 14:43:09 +0000schroyert226 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/success-breast-cancer-startup-challenge-inspires-second-challenge#commentsBringing Breast Cancer Technologies to Markethttp://ncifrederick.cancer.gov/about/theposter/content/bringing-breast-cancer-technologies-market-0
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tarasova-DSCF8129.jpg?itok=y9YgnQ67"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tarasova-DSCF8129.jpg?itok=y9YgnQ67" width="368" height="480" alt="Female scientist in laboratory" /><blockquote class="image-field-caption">
<p>CCR researcher and Breast Cancer Startup Challenge inventor Nadya Tarasova, Ph.D.</p>
</blockquote>
</figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>CCR research is recognized in novel competition to encourage the commercialization of breast cancer inventions.</em></p>
<p><em>Editor’s note: This article was originally published in </em><a href="http://home.ccr.cancer.gov/connections/2014/Vol8_No1/news_3.asp">CCR Connections</a><em> (Volume 8, No. 1). The Breast Cancer Startup Challenge</em> <em>was named one of six finalists in the </em><a href="http://www.hhs.gov/idealab/2014/07/21/hhs-innovates-celebrates-7th-round-of-innovations/"><em>HHS Innovates Award Competition</em></a><em>, and was one of three finalists recognized by HHS Secretary Sylvia Mathews Burwell and Deputy Secretary Bill Corr. For more information on the Challenge, see </em><a href="http://ncifrederick.cancer.gov/about/theposter/content/next-generation-entrepreneurs-ready-advance-breast-cancer-research-innovations-0"><em>previous article</em></a><em> on the Poster website. </em></p>
<p>Start-up companies are instrumental in bringing the fruits of scientific research to market. Recognizing an opportunity to bring entrepreneurial minds to bear on the diagnosis and treatment of breast cancer, the Avon Foundation for Women partnered with NCI and the Center for Advancing Innovation to launch the Breast Cancer Startup Challenge. The Challenge has brought together teams of university students and entrepreneurs to create strategic business plans to develop and commercialize patented technologies. Nine of the 10 inventions chosen in the competition were developed by scientists at NCI: five by CCR scientists and two by scientists formerly with CCR.</p>
<p>“NCI has always had a strong interest in fostering young investigators, and the fact that this challenge pairs each student team with entrepreneur-mentors to assist in the development of the business plans is another example of how we can bring new ideas and energy to cancer research,” said Douglas Lowy, M.D., Deputy Director of NCI and Chief of CCR’s Laboratory of Cellular Oncology.</p>
<p>The chosen technologies include cancer diagnostics, therapeutics, prognostics, one medical device, one vaccine, one delivery system, and one health IT system. The 10 winning teams will each be encouraged to launch start-up companies to develop the technologies.</p>
<p>One of the winning teams, based at Rutgers University in N.J., has formed a company called OncoLinx to push forward research into a class of cytotoxins that boost the effectiveness of antitumor agents. Developed by Nadya Tarasova, Ph.D., Head of the Synthetic Biologics and Drug Discovery Facility in CCR’s Cancer and Inflammation Program, the cytotoxins are easy to synthesize, stable in circulation, and are cell permeable. In an unpublished study, Tarasova and her colleagues discovered that when one of the cytotoxins was conjugated to the antibody Herceptin, the combined therapy killed 98 percent of cancer cells in vitro compared to 46 percent of cells killed by the antibody alone. An important step for the Rutgers team will be demonstrating the cytotoxins’ safety and effectiveness in preclinical studies. Key to this will be developing a method for transporting the cytotoxin directly to diseased cells within patients’ bodies, while avoiding surrounding healthy cells.</p>
<p>For any given cancer type, a number of treatment options exist. A major challenge for clinicians is determining which option is best for their patient without having to test them one by one. To address this issue, Stephen Hewitt, M.D., Ph.D., Staff Clinician in CCR’s Laboratory of Pathology, devised a tissue assay for up to four protein biomarkers. The presence or absence of the various biomarkers can indicate the optimal therapy for a patient and predict that patient’s survival rate for a given treatment. “The invention came out of a single study where we measured multiple biomarkers looking for a correlation between biomarker and drug response,” said Hewitt. “None of the biomarkers alone predicted response, but in ratios, based on the pathway interactions, they did.” A team of students at McGill University in Montreal has formed a company called ProVivoX that plans to develop a test based on Hewitt’s biomarker research that can predict breast cancer relapse. The team hopes to begin clinical trials by 2015.</p>
<p>Another particularly promising cancer therapy invented at CCR helps patients’ immune systems target tumors more effectively. Dennis Klinman, M.D., Ph.D., Senior Investigator in CCR’s Laboratory of Experimental Immunology, discovered a method for customizing synthetic immune system stimulators called CpG oligonucleotides that interact with immune cells that express Toll-like receptor 9 and thus drive an innate immune response. When linked to an apoptotic tumor cell vaccine derived from the patients’ own tumor biopsies, the oligonucleotide-vaccine conjugates reduce tumor size, as well as prevent cancer recurrence and metastasis in mice. A team from Washington University in St. Louis, Mo., plans to apply CpG oligonucleotides to triple-negative breast cancer. They also hope to expand their treatment, which is dubbed TheraProVax, to other cancer types.</p>
<p>As for Klinman, he appreciates the chance to see his research, as well as that of his colleagues, brought out of the lab and into the hands of doctors. “The Breast Cancer Startup Challenge provides a wonderful opportunity to focus on inventions for the treatment of cancer and improves the likelihood that they will find clinical application,” he said.</p>
<hr /><p><strong>CCR Inventions and Business Plan Winners*</strong></p>
<div>
<p><strong>Diagnostic from Biopsies with Software Analysis</strong><br /><strong>Category: </strong>Diagnostics/Health IT<br /><strong>Lead Inventor: </strong>Tom Misteli, Ph.D., CCR<br /><strong>Winner: </strong>University of Cambridge</p>
<p><strong>Immunotherapy Using Modified Self Tumor Cells</strong><br /><strong>Category: </strong>Therapeutic<br /><strong>Lead Inventor: </strong>Dennis Klinman, M.D., Ph.D., CCR<br /><strong>Winner: </strong>Washington University in Saint Louis</p>
<p><strong>Human Monoclonal Antibody-Based Cancer Therapies</strong><br /><strong>Category: </strong>Therapeutic, Diagnostic<br /><strong>Lead Inventor: </strong>Mitchell Ho, Ph.D., CCR<br /><strong>Winner: </strong>Stanford University</p>
<p><strong>Immunotherapy Using Granulysin Activated Monocytes</strong><br /><strong>Category: </strong>Therapeutic<br /><strong>Lead Inventor: </strong>Alan Krensky, M.D., Northwestern University (formerly with CCR)<br /><strong>Winner: </strong>Northwestern University</p>
<p><strong>Anticancer Toxin</strong><br /><strong>Category: </strong>Therapeutic<br /><strong>Lead Inventor: </strong>Nadya Tarasova, Ph.D., CCR<br /><strong>Winner: </strong>Rutgers, The State University of New Jersey</p>
<p><strong>Genomic-Based Diagnostic Assay</strong><br /><strong>Category: </strong>Diagnostics and Prognostic<br /><strong>Lead Inventor: </strong>Steven Libutti, M.D., Albert Einstein College of Medicine (formerly with CCR)<br /><strong>Winner: </strong>University of California, Berkeley</p>
<p><strong>Tissue-Based Diagnostic Assay</strong><br /><strong>Category: </strong>Diagnostic<br /><strong>Lead Inventor: </strong>Stephen Hewitt, M.D., Ph.D., CCR<br /><strong>Winner: </strong>McGill University</p>
<p>*This listing does not constitute CCR/NCI’s endorsement of the companies or potential products, and does not guarantee a grant of license for any federally owned technology.</p>
</div>
<hr /><p><em>To learn more about the Challenge, please visit </em><a href="http://www.breastcancerstartupchallenge.com/" target="_blank"><em>http://www.breastcancerstartupchallenge.com</em></a><em>.</em></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2014-july" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2014 July</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/science" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Science</a></li><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/people" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">People</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Wed, 30 Jul 2014 20:56:50 +0000schroyert175 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/bringing-breast-cancer-technologies-market-0#commentsNext-Generation Entrepreneurs Ready to Advance Breast Cancer Research Innovationshttp://ncifrederick.cancer.gov/about/theposter/content/next-generation-entrepreneurs-ready-advance-breast-cancer-research-innovations-0
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/3207_Biotech%20Logo-BC%20Startup.jpg?itok=_VjBnKiF"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/3207_Biotech%20Logo-BC%20Startup.jpg?itok=_VjBnKiF" width="480" height="241" alt="Breast Cancer Start-up Challenge logo" /></figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Michele Newton and Thomas Stackhouse, Contributing Writers, and Rosemarie Truman, Guest Writer</em></p>
<p><em>Editor’s note: In May 2014, the Breast Cancer Start-Up Challenge was named one of six finalists in the </em><a href="http://www.hhs.gov/idealab/pathways/hhs-innovates/"><em>HHS Innovates Award Competition</em></a><em>. This award celebrates innovations developed by employees of the U.S. Department of Health and Human Services (HHS) to support the mission of HHS. </em><em>In the final phase of the competition, the public will be invited to help select “The People’s Choice” winner; public voting takes place May 29 through June 6, 2014.</em> </p>
<p>Ten teams of business, legal, medical/scientific, engineering, and computer science students and seasoned entrepreneurs won the Business Plan Phase of the <a href="http://www.breastcancerstartupchallenge.com/">Breast Cancer Start-up Challenge</a>. Selected from an original field of 200 teams, these winners, plus two teams of finalists, will push forward to commercialize breast cancer–related inventions developed by inventors at the National Cancer Institute (NCI) and at an Avon Foundation–funded lab at Clemson University (see previous article posted in <a href="http://ncifrederick.cancer.gov/about/theposter/content/creating-start-companies-around-nci-inventions">January 2014</a>).</p>
<p>The trailblazing international competition focuses on bringing emerging breast cancer technologies to market through the creation of start-up businesses. The challenge was launched by <a href="http://www.thecenterforadvancinginnovation.org/">The Center for Advancing Innovation</a> (CAI), the <a href="http://www.avonfoundation.org/">Avon Foundation for Women</a>, and NCI.</p>
<p>The Avon Foundation is providing $250,000 in grants to support the competition.<img alt="Three men and a woman in a group photo." src="/about/theposter/sites/default/files/slideshow_images/TTC%20Breast%20Cancer_BCSC_0028-480x320.jpg" style="float:right; height:267px; margin:10px; width:400px" /></p>
<p>CAI extensively evaluated university challenges around the world to determine best practices. Through partnerships with NCI and the Avon Foundation, CAI was able to conduct a detailed assessment of the NCI patent portfolio as well as the Avon Foundation grantee portfolio. This process resulted in identifying the most promising inventions for this type of challenge.</p>
<p>Not only does this challenge mark the first time a therapeutically oriented foundation has sponsored a contest to launch start-up businesses, but it is also the first time a federal lab has put its inventions in a university-based start-up contest.</p>
<p><strong>Supporting a Presidential Directive</strong></p>
<p>The challenge supports <a href="http://www.whitehouse.gov/the-press-office/2011/10/28/presidential-memorandum-accelerating-technology-transfer-and-commerciali">President Obama’s directive</a> that federal agencies with research facilities accelerate the transfer of innovations from the laboratory to the commercial marketplace. Ten inventions—nine from NCI and one funded by the Avon Foundation—were selected for the challenge.</p>
<p>Teams developed a 10-page business plan, a five-minute live pitch, and a one-minute elevator speech. A <a href="http://www.breastcancerstartupchallenge.com/judges.html">panel of judges</a> with diverse expertise reviewed submissions and determined the winners.</p>
<p>The teams will have access to a one- to three-year mentorship program, known as a “Global Accelerator,” which is designed to create a high probability of success for the winning teams and their start-ups. As such, a network of coaches from NCI, NIH, CAI, the venture capital community, and strategy consultants will provide hands-on support in the areas of development, commercialization, and regulatory strategies/plans. Successful start-ups will be announced in the summer of 2014.</p>
<p>Looking ahead, CAI and NCI are evaluating opportunities to institutionalize and expand this model in order to speed the delivery of other federal biomedical inventions to the marketplace.</p>
<p><strong><img alt="A speaker in front of an audience" src="/about/theposter/sites/default/files/slideshow_images/TTC%20Breast%20Cancer_BCSC_0033-480x320.jpg" style="float:left; height:287px; margin:10px; width:400px" />NCI Inventions and Inventors in the Breast Cancer Start-up Challenge</strong></p>
<p>Of the 10 inventions selected for the challenge, nine were from NCI (see below), and three of those were from NCI at Frederick. The one-minute pitches may be viewed on the <a href="http://www.youtube.com/user/BCStartupChallenge">Challenge’s YouTube site</a>.</p>
<ul><li>Cancer Immunotherapy Using Oligonucleotides Conjugated to Apoptotic Tumor Cells, Dennis Klinman and Hidekazu Shirota (NCI at Frederick)</li>
<li>Potent, Easy-to-Use, Targeted Toxins for Anti-tumor Agents, Nadya Tarasova et al. (NCI at Frederick)</li>
<li>Virus-Like Particles as a Platform for Efficient Delivery of Proteins and RNA, Stan Kaczmarczyk and Deb Chatterjee (NCI at Frederick)</li>
<li>Breast Cancer Diagnostic Based on Spatial Organization of Genes in the Cell Nucleus, Tom Misteli and Karen Meaburn</li>
<li>Human Monoclonal Antibody Targeted to Mesothelin for the Treatment of Cancer, Mitchell Ho et al.</li>
<li>Use of 15 kDa Granulysin as an Adjuvant through Activation of Dendritic Cells, Alan Krensky and Carol Clayberger</li>
<li>Prediction of Breast Cancer Survival Using Expression Levels of Six Genes, Steven Libutti and Mei He</li>
<li>Ratio-Based Biomarkers for the Prediction of Cancer Survival, Stephen Hewitt and Joon Yong Chung</li>
<li>Biomarker for the Prediction of Taxane-Based Chemotherapy Outcome, Sherry Yang and Sandra Swain</li>
</ul><p><em>Rosemarie Truman is founder and chief executive officer of The Center for Advancing Innovation.</em></p>
<p><strong>NCI Technology Transfer Center at Frederick<img alt="Speaker at podium." src="/about/theposter/sites/default/files/slideshow_images/TTC%20Breast%20Cancer_BCSC_0030-480x317.jpg" style="float:right; height:379px; margin:10px; width:250px" /></strong></p>
<p>The NCI Technology Transfer Center (TTC) played a critical role in the Breast Cancer Start-up Challenge. A confidential disclosure agreement was drafted by TTC, and more than 400 individual agreements were signed to accomplish the collaborative work performed in this challenge. </p>
<div>
<p>Collaboration is frequently key to accomplishing research goals, and TTC is focused on guiding discoveries on the path to commercialization. Through a specialized team, TTC protects and promotes NIH intellectual property, allowing researchers to focus on what they do best—research, discover, and develop. Contact the TTC office if you have any questions or are not sure which agreement is appropriate for your research situation.</p>
<p>Telephone: 301-845-5465<br />
Website: <a href="http://ttc.nci.nih.gov/" style="line-height: 1.6em;" target="_blank">http://ttc.nci.nih.gov</a><br />
Follow us on Twitter: <a href="http://twitter.com/NCITechTransfer" style="line-height: 1.6em;" target="_blank">http://twitter.com/NCITechTransfer</a><br />
Join our LinkedIn Group: <a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="line-height: 1.6em;" target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
<div> </div>
<p>Photo captions (top to bottom)</p>
<ol><li>From left: Bryan Sivak, chief technology officer, HHS; Marc Hurlbert, executive director, Avon Foundation; Rosemarie Truman, founder and chief executive officer, The Center for Advancing Innovation; Thomas Stackhouse, associate director, Technology Transfer Center, NCI. Photo courtesy of Daniel Sone, NCI.</li>
<li>Bryan Sivak speaks at the Business Plan Phase Awards Ceremony. Photo courtesy of Daniel Sone, NCI.</li>
<li>Thomas Stackhouse addresses winning teams during the Business Plan Phase Awards Ceremony. Photo courtesy of Daniel Sone, NCI.</li>
</ol></div>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2014-may" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2014 May</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Thu, 22 May 2014 14:10:54 +0000schroyert156 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/next-generation-entrepreneurs-ready-advance-breast-cancer-research-innovations-0#commentsCreating Start-up Companies around NCI Inventionshttp://ncifrederick.cancer.gov/about/theposter/content/creating-start-companies-around-nci-inventions
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/3207_Biotech%20Logo-Breast%20Cancer%20Startup.jpg?itok=3ROIcLay"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/3207_Biotech%20Logo-Breast%20Cancer%20Startup.jpg?itok=3ROIcLay" width="480" height="241" alt="Driving Innovation in Breast Cancer (Breast Cancer Startup Challenge) graphic." /></figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Karen Surabian, Thomas Stackhouse, and Rose Freel, Contributing Writers, and Rosemarie Truman, Guest Writer</em></p>
<p>The National Cancer Institute (NCI), led by the Technology Transfer Center (TTC), the Avon Foundation, and The Center for Advancing Innovation have partnered to create a “first-of-a-kind” Breast Cancer Start-up Challenge.</p>
<p>The Challenge features 10 breast cancer inventions (nine from NCI and one from the Avon Foundation) that have commercial viability and are important to public health (see below). The primary goal of the Challenge is to stimulate the creation of start-up businesses based on these inventions. </p>
<h2><strong>Team Members Represent Wide Range of Experience</strong></h2>
<p>A global effort, the Challenge comprises teams made up of university students, postdocs, and medical residents; seasoned entrepreneurs; and collaborators, mentors, and advisers. Each team will create a business plan using the invention as the basis for a potential start-up company.</p>
<p>Forty-six teams are participating, with members from 48 universities in Canada, India, the Netherlands, New Zealand, United Kingdom, and the United States. </p>
<p>The Challenge will be completed in three phases:</p>
<ol><li>Letter of Intent (this phase is now complete): Teams provide information regarding the members of their team and indicate how team members meet eligibility requirements. Teams also outline their intent to participate in the Challenge.</li>
<li>Business Plan: Teams develop a 10-page business plan or business model canvas; a five-minute “live” pitch; and a one-minute elevator speech via recorded video.</li>
<li>Start-up: Teams incorporate their start-up and apply for seed funding.</li>
</ol><p>Winners of the Business Plan phase will be announced in February 2014, and the successful start-ups will be announced in the summer of 2014.</p>
<table align="right" style="width:400px"><tbody><tr><td>
<h2>NCI Inventions and Inventors Breast Cancer Start-up Challenge</h2>
<ul><li><em>Cancer Immunotherapy Using Oligonucleotides Conjugated to Apoptotic Tumor Cells</em>, Dennis Klinman and Hidekazu Shirota (NCI at Frederick)</li>
<li><em>Potent, Easy-to-Use, Targeted Toxins for Anti-tumor Agents</em>, Nadya Tarasova et al. (NCI at Frederick)</li>
<li><em>Virus-Like Particles as a Platform for Efficient Delivery of Proteins and RNA</em>, Stan Kaczmarczyk and Deb Chatterjee (NCI at Frederick)</li>
<li><em>Breast Cancer Diagnostic Based on Spatial Organization of Genes in the Cell Nucleus</em>, Tom Misteli and Karen Meaburn</li>
<li><em>Human Monoclonal Antibody Targeted to Mesothelin for the Treatment of Cancer</em>, Mitchell Ho, et al.</li>
<li><em>Use of 15 kDa Granulysin as an Adjuvant through Activation of Dendritic Cells</em>, Alan Krensky and Carol Clayberger</li>
<li><em>Prediction of Breast Cancer Survival Using Expression Levels of Six Genes</em>, Steven Libutti and Mei He</li>
<li><em>Ratio-Based Biomarkers for the Prediction of Cancer Survival</em>, Stephen Hewitt and Joon-Yung Chung</li>
<li><em>Biomarker for the Prediction of Taxane-Based Chemotherapy Outcome</em>, Sherry Yang and Sandra Swain</li>
</ul></td>
</tr></tbody></table><h2><strong>Highlights of the Challenge</strong></h2>
<ul><li>Of the nine NCI inventions included in the Challenge, three are from NCI at Frederick labs.</li>
<li>The teams are made up of an average of nine members, representing legal, medical/scientific, and business fields, as well as a seasoned entrepreneur on each team.</li>
<li>On average, there are two universities represented on each team.</li>
<li>A confidential disclosure agreement was drafted by TTC, and 431 individual agreements have been signed.</li>
</ul><p>Media outlets, including <a href="http://www.biocenturytv.com/player/2732726963001/2733441564001?utm_medium=web&amp;utm_source=video_link&amp;utm_campaign=bctv_link_to_program">CBS News</a>, the <a href="http://www.biotech-now.org/business-and-investments/2013/09/driving-innovation-in-breast-cancer-startup-challenge#frameId=jim-frame&amp;height=485">Biotechnology Industry Organization</a> (BIO), the <a href="http://www.multibriefs.com/briefs/autm/autm091913.php">Association of University Technology Managers</a> (AUTM), and the <a href="http://www.flcmidatlantic.org/events.html">Federal Laboratory Consortium for Technology Transfer</a> (FLC), as well as White House officials, have announced the Challenge.</p>
<p>Although the Challenge is no longer accepting new teams, you can support the effort by spreading the word and following the Challenge on <u><a href="http://www.linkedin.com/groups?gid=7419780">LinkedIn</a></u>, <u><a href="https://www.facebook.com/thebreastcancerstartupchallenge">Facebook</a></u>, <u><a href="http://www.youtube.com/BCStartupChallenge">YouTube</a></u>, and <u><a href="https://twitter.com/TheBCSChallenge">Twitter</a></u>. For more information, including a complete description of the inventions, teams, and participating universities, visit: <a href="http://www.breastcancerstartupchallenge.com">http://www.breastcancerstartupchallenge.com</a>.</p>
<p><em>Ros</em><em>emarie Truman </em><em>is founder</em><em> and </em><em>chief executive officer of The Center for Advancing Innovation, Inc.</em></p>
<p><strong>If You Are Not Sure, Ask</strong></p>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" style="color: rgb(7, 130, 193); " target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" style="color: rgb(7, 130, 193); " target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="color: rgb(7, 130, 193); " target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2014-january" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2014 January</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Mon, 30 Dec 2013 15:13:16 +0000meyerjp78 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/creating-start-companies-around-nci-inventions#commentsBefore You Collaborate, You Should Partner with NCI TTChttp://ncifrederick.cancer.gov/about/theposter/content/you-collaborate-you-should-partner-nci-ttc
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer_FNL1119.jpg?itok=O3uM2FNP"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer_FNL1119.jpg?itok=O3uM2FNP" width="480" height="320" alt="NCI Technology Transfer Center staff" /><blockquote class="image-field-caption">
<p>NCI Technology Transfer Center (TTC) staff (Frederick). Center: Tom Stackhouse, Ph.D., associate director; surrounded by (left to right) Rose Freel, Jasmine Yang, Heidi Bowman, Kevin Brand, Chris Sappington, Jeff Thomas, Mike Currens, Joseph Miles, Kathy Higinbotham, Donna Bialozor, and Karen Surabian.</p>
</blockquote>
</figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Karen Surabian, Thomas Stackhouse, and Jeffrey W. Thomas, Contributing Writers</em></p>
<p>As the fall and winter seasons progress, you may be attending more scientific conferences, where you may find a number of opportunities for research collaborations.</p>
<p>To assist your lab in reaching its research goals through collaborations, the staff of the National Cancer Institute Technology Transfer Center (NCI TTC) can guide you through a tool box of agreements you may need for protecting your intellectual property (IP) and effectively managing your collaboration. </p>
<p>NCI TTC is the IP and partnership liaison for the NCI laboratories and scientists. NCI TTC manages the NCI patent portfolio and negotiates transactional agreements with outside parties (universities, pharmaceutical and biotechnology companies, and other research organizations) to formalize collaborative partnerships. </p>
<p><strong>Employee Discovery and Invention Reports (EIRs)</strong> describe your invention, list the possible inventors, and assign patent ownership to the U.S. government. </p>
<p>Managing discoveries through future research collaboration must be balanced with any potential commercial development. Moving your discovery into the hands of physicians and patients, where it can be of most benefit, is a critical, yet complex, process requiring a team of experts from many different fields. The starting line for this process is the reporting of your discovery.</p>
<p>A reportable invention includes, but is not limited to, organisms, such as mice, as well as compounds, assays, machines, software, methods of manufacture, and methods of use.</p>
<p>A disclosure may include, but is not limited to, posters, presentations, abstracts and journal articles (including electronic), and even job interviews with non-NIH personnel. You are advised to submit an EIR before—preferably three months before—a disclosure.</p>
<p>To ensure that the EIR is filled out and managed properly, your NCI TTC specialist will assist you in completing the EIR form; coordinate the reviews of EIRs; work on your behalf with the NIH Office of Technology Transfer regarding filing and licensing of your patent applications; and work with other NIH offices such as the Office of General Counsel and other NIH institute technology transfer offices.</p>
<h2><strong>Types of Collaborative Agreements</strong></h2>
<p><img alt="Technology Transfer at NCI graphic" src="/about/theposter/sites/default/files/slideshow_images/Tech_graphic-11-25-2013.jpg" style="border-style:solid; border-width:0px; float:right; height:446px; margin:10px; width:400px" />NCI TTC staff is experienced in negotiating several types of transactional agreements, as outlined below. Your situation will be assessed individually, so that the proper agreement(s) may be drafted with your goals, as well as those of your collaborator, in mind. </p>
<p><strong>1. Confidential Disclosure Agreements (CDAs)</strong> are used for various situations in which confidential, proprietary, and/or unpublished information will be disclosed between parties. The flow of the information may be in one direction (e.g., from your laboratory to the collaborating organization) or may be in multiple directions (e.g., back and forth between your laboratory and multiple collaborating organizations). </p>
<p>Disclosure of confidential information before filing a patent application may have an adverse impact on certain patent rights and other IP issues. This is especially true now that we are operating under the new patent law of the America Invents Act. Therefore, when submitting your EIR, you also should think about your communications associated with unpublished information/data. That is where the Confidential Disclosure Agreement (CDA) becomes important to protect your work.</p>
<p>If you are considering disclosure of confidential proprietary and/or unpublished information to an outside party, please contact NCI TTC for assistance in executing the most appropriate agreement. </p>
<p><strong>2. Material Transfer Agreements (MTAs</strong>) are used to exchange proprietary research materials either into or out of NCI and to document the source of the materials. These agreements are important because they offer NCI scientists protection related to issues of publication and use of materials for research purposes; MTAs may also include terms to protect confidential and/or unpublished information. </p>
<p>NCI TTC recognizes that the exchange of important, and often unique, research materials is critical to your work. Some materials require special attention because they may be related to human subject materials or other special circumstances. Before transferring or exchanging materials with outside organizations, contact NCI TTC, whose staff is trained to navigate you through any unique transfer situations. </p>
<p>One special type of MTA is a Collaboration Agreement (CA), which contains a jointly defined research plan and permits the exchange of confidential information, as well as materials, both to and from the collaborator. </p>
<p><strong>3. Clinical Trial Agreements (CTAs) </strong>are used for studies conducted in humans to determine the safety and efficacy of agents and devices brought in from outside parties.</p>
<p>If your laboratory becomes involved in working on research that leads to clinical trials, you should contact NCI TTC for help in negotiating CTAs. These agreements enable you to transfer a patented, investigational agent only from a collaborator to NCI for NCI-sponsored clinical trials. </p>
<p>CTAs offer no promises to future IP rights, but do allow for access to data for filings with the U.S. Food and Drug Administration. These agreements are executed with the expectation that the collaborator has already completed preclinical and Investigational New Drug–directed toxicity studies. They specify the use of the investigational agent in humans and reporting requirements for adverse drug reactions. </p>
<p><strong>4. Cooperative Research and Development Agreements (CRADAs)</strong> are collaboration agreements, usually with a commercial partner, that specify terms of confidentiality and an exclusive option to the collaborator to license future inventions. The CRADA allows for funds to be provided to the NIH laboratory to support its part of the research being conducted under the CRADA. However, NIH is not permitted to provide funding to the outside collaborator under the CRADA. </p>
<p>CRADAs provide for the exchange of material, equipment, and personnel, and are used when NIH and industry collaborate to develop a technology for commercialization. There are many types of CRADA collaborations, and NCI TTC will assist your team in navigating them and negotiating the best terms to protect your research while advancing the discovery.</p>
<h2><strong>If You Are Not Sure, Ask</strong></h2>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2013-november" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2013 November</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Mon, 25 Nov 2013 16:54:00 +0000meyerjp90 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/you-collaborate-you-should-partner-nci-ttc#commentsNineteen Patents Issued in 2012 for Inventions by Frederick Researchershttp://ncifrederick.cancer.gov/about/theposter/content/nineteen-patents-issued-2012-inventions-frederick-researchers
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/July%202013%20Article%20graphic-2.jpg?itok=VZzop_9S"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/July%202013%20Article%20graphic-2.jpg?itok=VZzop_9S" width="480" height="373" alt="Scientific figure" /><blockquote class="image-field-caption">
<p>The figure, representing US Patent 8,198,402 (Smoothened polypeptides and methods of use), illustrates the design principle used for generating the Hedgehog pathway inhibitors disclosed in the patent: folding the inhibitors through an interaction with the cellular membrane. Membrane anchoring through lipidation allows the membrane to facilitate the folding of short protein fragments and the conversion of these fragments into potent inhibitors of the corresponding protein. Folding the inhibitors into the appropriate conformation is critical to their activity.</p>
</blockquote>
</figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Karen Surabian, Contributing Writer</em></p>
<p>Patents provide a period of exclusivity and are a way to exclude others from making, using, or selling an inventor’s novel technology. For the National Institutes of Health (NIH), patents are an incentive for an outside party to license, develop, and commercialize NIH technologies that will benefit public health, especially those that require substantial further development by an outside party, such as therapeutics and diagnostics. Licensing these inventions to others willing to commercialize the technology fosters the development of the technology into a useful product.</p>
<p>The NIH Office of Technology Transfer (OTT) licenses technologies that are invented at NIH and works with the NCI Technology Transfer Center (TTC) to process patent applications on selected inventions. In addition, NCI TTC and NIH OTT work with outside partners using a variety of mechanisms to facilitate the commercial development of NIH technologies.</p>
<p>Mechanisms to access NIH materials for research or commercial development, or to partner with NIH in a collaborative project may include Material Transfer Agreements (MTAs), Confidential Disclosure Agreements (CDAs), Cooperative Research and Development Agreements (CRADAs), other types of collaborative agreements, and licenses (non-exclusive and exclusive).</p>
<h2>Patents Issued in 2012</h2>
<p><strong>Anti-viral griffithsin compounds, compositions, and methods of use.</strong> Inventors: Barry O’Keefe,* Toshiyuki Mori,* and James McMahon* (US 8,088,729; issued January 3)</p>
<p><strong>Nitric oxide–releasing diazeniumdiolated compounds.</strong> Inventors: Joseph Hrabie,* Frank DeRosa,* and Larry Keefer* (US 8,093,343; issued January 10)</p>
<p><strong>Human monoclonal antibodies that specifically bind IGF-II.</strong> Inventors: Dimiter Dimitrov* and Yang Feng* (US 8,105,598; issued January 31)</p>
<p><strong>Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency.</strong> Inventors: Dimiter Dimitrov* and Mei-Yun Zhang* (US 8,110,192; issued February 7)</p>
<p><strong>Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter.</strong> Inventors: Rando Allikmets,* Kent Anderson, Michael Dean,* Mark Leppert,* Richard Lewis, Yixin Li, James Lupski, Jeremy Nathans, Amir Rattner, Noah Shroyer, Nanda Singh, Philip Smallwood, and Hui Sun (US 8,129,353; issued March 6)</p>
<p><strong>In situ assembling of protein microarrays.</strong> Inventors: Deb Chatterjee,* Kalavathy Sitaraman,* James Hartley,* Cassio Baptista,* and David Munroe* (US 8,148,302; issued April 3)</p>
<p><strong>Potent combinations of MRNA transport elements.</strong> Inventors: Barbara Felber,* Sergey Smulevitch,* and George Pavlakis* (US 8,163,542; issued April 24)</p>
<p><strong>Inactivators of 06-alkylguanine-DNA alkytransferase.</strong> Inventors: Robert Moschel,* Matthew Karl Moschel (legal representative), Anthony Pegg, Sahar Javanmard,* Natalia Loktionova, and Gary Pauly* (US 8,188,055; issued May 29)</p>
<p><strong>Smoothened polypeptides and methods of use.</strong> Inventors: Nadya Tarasova,* Michael Dean,* and Hong Lou* (US 8,198,402; issued June 12)</p>
<p><strong>Inhibitor of DNA methylation.</strong> Inventors: Eric Selker, Cindy Matsen, Peter Jones, Jonathan Cheng, Sheldon Greer, and Victor Marquez* (US 8,207,142; issued June 26)</p>
<p><strong>Method of treating pneumoconiosis with oligodeoxynecleotides.</strong> Inventors: Dennis Klinman* and Takashi Sato* (US 8,222,225; issued July 17)</p>
<p><strong>HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants.</strong> Inventors: De Yang,* Joost Oppenheim,* and Michael Bustin* (US 8,227,417; issued July 24)</p>
<p><strong>Inhibitors of ubiquitin E1.</strong> Inventors: Allan Weissman,* Yili Yang,* and Jane Jensen* (US 8,242,160; issued August 14)</p>
<p><strong>Fast electron paramagnetic resonance imaging (EPRI) in the CW EPR mode using rapid-scan in the presence of rotating gradients and direct detection with transmit/receive and data processing in a digital signal processing platform.</strong> Inventors: Sankaran Subramanian,<sup>#</sup> Nallathamby Devasahayam,<sup>#</sup> Janusz Koscielniak,* James Mitchell,<sup>#</sup> and Murali Krishna Cherukuri<sup>#</sup> (US 8,242,778; issued August 14)</p>
<p><strong>Cellular and viral inactivation.</strong> Inventors: Yossef Raviv,* Mathias Viard,* and Robert Blumenthal* (US 8,268,602; issued September 18)</p>
<p><strong>Fast electron paramagnetic resonance imaging (EPRI) using CW EPR spectrometer with sinusoidal rapid-scan and digital signal processing.</strong> Inventors: Sankaran Subramanian,<sup>#</sup> Nallathamby Devasahayam,<sup>#</sup> Janusz Koscielniak,* James Mitchell,<sup>#</sup> and Murali Krishna Cherukuri<sup>#</sup> (US 8,269,496; issued September 18)</p>
<p><strong>Treating renal cancer using 4-[bis] 2-[(methylsulfonyl) oxy] ethyl] amino]-2-methyl-benzaldehyde.</strong> Inventors: Susan Mertins,* Susan Bates,<sup>#</sup> David Covell,* Geoffrey Patton,* Melinda Hollingshead,* and Rao Vishnuvajjalla<sup>#</sup> (US 8,273,797; issued September 25)</p>
<p><strong>Inactivated influenza virus compositions.</strong> Yossef Raviv,* Mathias Viard,* Robert Blumenthal,* Robert Hogan, and Stephen Mark Tompkins (US 8,278,083; issued October 2)</p>
<p><strong>Viral chemokine-antigen fusion proteins.</strong> Inventors: Larry Kwak* and Bira Arya* (US 8,318,177; issued November 27)</p>
<p>Marketing efforts for these technologies by NCI TTC and NIH OTT have led to many collaborations and licenses. For example, US Patent 8,198,402 (Smoothened polypeptides and methods of use; see figure) was licensed and is also part of a CRADA with a start-up company to commercially develop the technology. In addition, the technology was part of a nomination entitled “Novel Protein-Like Therapeutics for the Treatment of Cancer,” for which NCI researchers Nadya Tarasova, Ph.D., Synthetic Biologics and Drug Discovery Facility; Michael Dean, Ph.D., Laboratory of Experimental Immunology; and Sergei Tarasov, Ph.D., Structural Biophysics Laboratory; and former NCI researcher Hong Lou, Ph.D., received an award for excellence in technology transfer from the Federal Laboratory Consortium (FLC) Mid-Atlantic Region, and an honorable mention at the National 2011 FLC Awards.</p>
<p>*Denotes researchers who were with NCI at Frederick (NCI and SAIC-Frederick) at the time the patent was submitted.</p>
<p><sup>#</sup>Denotes researchers who were with NCI Bethesda at the time the patent was submitted.</p>
<p>Special thanks to Mojdeh Bahar, J.D., M.A., CLP (chief, Cancer Branch, NIH OTT), Christopher Sappington (technology development administrative specialist, TTC, NCI), and Tere Diaz (technology development administrative specialist, TTC, NCI) for helping to compile the list of patents.</p>
<h2><strong>If You Are Not Sure, Ask</strong></h2>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" style="color: rgb(7, 130, 193); " target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" style="color: rgb(7, 130, 193); " target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="color: rgb(7, 130, 193); " target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
<p> </p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2013-august" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2013 August</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Sat, 31 Aug 2013 15:07:00 +0000meyerjp119 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/nineteen-patents-issued-2012-inventions-frederick-researchers#commentsNew Website Helps You Find What You Needhttp://ncifrederick.cancer.gov/about/theposter/content/new-website-helps-you-find-what-you-need
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer-April.jpg?itok=mlLhH5ZS"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer-April.jpg?itok=mlLhH5ZS" width="480" height="372" alt="Website screenshot" /><blockquote class="image-field-caption">
<p>The NCI TTC’s redesigned website provides an inviting, user-friendly environment.</p>
</blockquote>
</figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Karen Surabian, Contributing Writer</em></p>
<p>The National Cancer Institute’s Technology Transfer Center (NCI’s TTC) recently launched a redesign of its website. New graphics, color scheme, and updated features provide a user-friendly environment for finding information related to technology transfer at NCI.</p>
<p>You’ll be able to easily navigate the new TTC website for information about invention reporting, transferring materials and information, and collaborating/ partnering with NCI. Begin on the home page to review interesting news and events related to technology transfer at NIH.</p>
<p>You can also “get connected” to TTC by linking to a form for requesting general or specific information, as well as by signing up for e-mail alerts for co-development opportunities.</p>
<h2>Tabs Categorize Major Topics</h2>
<p>Tabs at the top of the page will help you quickly find major topics from anywhere on the website. Here’s what you’ll find when you click on each of the tabs:</p>
<p><strong>“Standard Forms &amp; Agreements” </strong>brings you to frequently used agreements, including Material Transfer Agreements (MTAs), Confidential Disclosure Agreements (CDAs), and Cooperative Research and Development Agreements (CRADAs) as well as the Employee Invention Report (EIR) form.</p>
<p><strong>“Co-Development &amp; Resources”</strong> brings you to descriptions of technologies in development. Outside parties (usually companies) may review these descriptions to determine their level of interest in partnering with an NCI scientist to further develop the technology or in licensing it directly.</p>
<p><strong>“Careers &amp; Training” </strong>links you to various training opportunities from different organizations as well as to information about TTC’s Fellowship Program, which comprises the marketing track and the agreement negotiation track.</p>
<p><strong>“Intellectual Property &amp; Inventions” </strong>brings you to useful resources regarding patenting and inventions as well as links to information about reporting an invention and keeping laboratory notebooks for patenting purposes.</p>
<p><strong>“About TTC”</strong> brings you to a description of the role of TTC and how it supports the technology development activities of NCI and other institutes within NIH.</p>
<h2>How You Can Add to the TTC Website</h2>
<p>TTC invites you to explore its new website and provide feedback on its features. Here’s how:</p>
<ul><li>Sign up to receive more information about co-development opportunities.</li>
<li>Pass along this information to colleagues, both in or outside your laboratory.</li>
<li>Check out the information on intellectual property and inventions, including the “Guide for Keeping Laboratory Records.”</li>
<li>Check out some of the training opportunities.</li>
<li>Check out the news and events on the homepage.</li>
<li>Contact TTC at 301-846-5465 with your ideas and comments, questions, or interesting news items to be considered for posting on the site.</li>
</ul><p><strong>NCI Technology Transfer Center </strong><a href="http://ttc.nci.nih.gov/index.php" target="_blank"><strong>http://ttc.nci.nih.gov/index.php</strong></a></p>
<p>Useful links:</p>
<p>“How to Report an Invention” and “Guide for Keeping Laboratory Records”: <a href="http://ttc.nci.nih.gov/ip/report.php" target="_blank">http://ttc.nci.nih.gov/ip/report.php</a></p>
<p>Co-Development Opportunities: <a href="http://ttc.nci.nih.gov/opportunities/available.php" target="_blank">http://ttc.nci.nih.gov/opportunities/available.php</a></p>
<p>Information Request Form: <a href="http://techtransfer.cancer.gov" target="_blank">http://techtransfer.cancer.gov</a></p>
<h2><strong>If You Are Not Sure, Ask</strong></h2>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" style="color: rgb(7, 130, 193); " target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" style="color: rgb(7, 130, 193); " target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="color: rgb(7, 130, 193); " target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2013-april" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2013 April</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li></ul></section>Tue, 30 Apr 2013 16:56:00 +0000meyerjp118 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/new-website-helps-you-find-what-you-need#commentsCRADAs: They're Not Just for NCI Anymorehttp://ncifrederick.cancer.gov/about/theposter/content/cradas-theyre-not-just-nci-anymore
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer_DSC8569_0.jpg?itok=WTcfi6q7"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/Tech%20Transfer_DSC8569_0.jpg?itok=WTcfi6q7" width="480" height="319" alt="Two hands shaking." /></figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Karen Surabian, Thomas Stackhouse, and Jeffrey Thomas, Contributing Writers, and Bruce Crise, Guest Writer</em></p>
<p>Advancing scientific discovery is increasingly dependent on diverse and innovative partnerships, and the Cooperative Research and Development Agreement (CRADA) is an essential tool for establishing partnerships. CRADAs allow a federal laboratory to enter into collaborative research and development (R&amp;D) projects with outside parties (commercial or nonprofit).</p>
<p>CRADAs have been successfully used at NCI for more than two decades, and they have led to several effective products, including Avastin (for certain types of colorectal, lung, and renal cancer, as well as glioblastoma) and Velcade (for multiple myeloma).</p>
<p>As the contractor operating a government-owned, contractor-operated facility like the Frederick National Laboratory for Cancer Research (FNL), SAIC-Frederick also has the legal authority to engage in CRADAs, but to date has not had an official program for CRADAs.</p>
<h2><strong>New c-CRADA Allows Contractor to Partner Independently</strong></h2>
<p>Recently, administrative staff from both SAIC-Frederick and NCI received approval for the contractual and policy modifications necessary to launch a contractor CRADA (c-CRADA) program at FNL.</p>
<p>Under the c-CRADA, SAIC-Frederick initiates and manages CRADA projects that do not involve direct participation from NCI staff in the research. Procedures have been established to effectively identify potential c-CRADA partners, develop the prospective c-CRADA project with the partner, review and approve the c-CRADA, and monitor the progress of the R&amp;D project. Under these agreements, NIH CRADA subcommittee approval is not required; instead, c-CRADAs are approved locally by the NCI contracting officer, with input from the NCI technology transfer and program staff.</p>
<p>The new c-CRADA program was established to enhance partnering opportunities highlighting the contractor’s unique capabilities at FNL. These unique capabilities and the construction of the Advanced Technology Research Facility (ATRF), whose primary function is to foster partnerships, are the driving forces behind the c-CRADA program.</p>
<h2><strong>Two Kinds of Agreements Are in Place</strong></h2>
<p>Two c-CRADA “templates,” or model agreements, have been developed. The simpler of the two, the Technical Service Agreement (TSA), allows a partner to select from a list of unique FNL services for a set cost. TSAs are most appropriate for projects requiring a quick turnaround from the initial request through the provision of the final data package to the partner.</p>
<p>Second, the “full” c-CRADA is analogous to the NCI CRADA in that it anticipates a larger, joint R&amp;D project with the partner. c-CRADAs are designed to accommodate the development of new technologies that might be used in the broader FNL research community in support of NCI’s mission, or by the public to benefit patients.</p>
<p>Both types of c-CRADAs provide access to the extensive scientific and technical expertise of the staff at FNL.</p>
<h2><strong>NCI CRADA versus c-CRADA</strong></h2>
<p>The type of agreement used (NCI CRADA, TSA, or full c-CRADA) depends on the specific circumstances of the proposed project. For example, all CRADAs enable both parties to provide resources, personnel, and equipment for the joint research. They also allow for external funding to support the research and grant the CRADA partner with a first option to elect an exclusive or non-exclusive commercialization license to inventions made under the CRADA.</p>
<p>However, inventions made by contractor (i.e., SAIC-Frederick) employees under the c-CRADA are managed by the contractor, rather than being assigned to and managed by the government, as required by an NCI CRADA.</p>
<p>In addition, although NCI staff may not directly participate in the research project of a c-CRADA, SAIC-Frederick staff may participate in projects established under NCI CRADAs. The latter remains unchanged from the past, and allows the unique resources and expertise of the SAIC-Frederick programs and labs to be used in collaborative projects between NCI and an outside partner.</p>
<h2><strong>Who Benefits?</strong></h2>
<p>Adding the TSA and c-CRADA to the expanding toolbox for technology transfer will assist FNL laboratories in streamlining R&amp;D activities. Ultimately, these agreements enable more rapid development of new technologies and treatments for people living with cancer, AIDS, or other infectious disease.</p>
<p>The NCI Technology Transfer Center and the SAIC-Frederick Partnership Development Office can work with you to develop proposed partnership concepts and implement the appropriate agreement. For information, please call 301-846-5465.</p>
<p><em>Bruce Crise, Ph.D., is director of the Partnership Development Office, SAIC-Frederick.</em></p>
<h2><strong>If You Are Not Sure, Ask</strong></h2>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" style="color: rgb(7, 130, 193); " target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" style="color: rgb(7, 130, 193); " target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="color: rgb(7, 130, 193); " target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2012-december" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2012 December</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/crada" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">CRADA</a></li></ul></section>Wed, 05 Dec 2012 13:00:00 +0000schroyert58 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/cradas-theyre-not-just-nci-anymore#commentsNew Location Improves Efficiencyhttp://ncifrederick.cancer.gov/about/theposter/content/new-location-improves-efficiency
<div class="field field-name-field-image field-type-image field-label-hidden view-mode-rss"><div class="field-items"><figure class="clearfix field-item even" rel="og:image rdfs:seeAlso" resource="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/TTC_IP01.jpg?itok=_K3OUH4Y"><img typeof="foaf:Image" class="image-style-large" src="http://ncifrederick.cancer.gov/about/theposter/sites/default/files/styles/large/public/field/image/TTC_IP01.jpg?itok=_K3OUH4Y" width="480" height="329" alt="Two women talking." /><blockquote class="image-field-caption">
<p>Jennifer Troyer (left), a senior scientist in the Laboratory of Molecular Technology, consults with Courtney Silverthorn, an IP specialist, in the atrium of the ATRF. The SAIC-Frederick IP Office often works with scientists from the Advanced Technology Program.</p>
</blockquote>
</figure></div></div><div class="field field-name-body field-type-text-with-summary field-label-hidden view-mode-rss"><div class="field-items"><div class="field-item even" property="content:encoded"><p><em>By Nancy Parrish, Staff Writer</em></p>
<p>The physical proximity of the SAIC-Frederick Intellectual Property (IP) Office to the NCI Technology Transfer Center (NCI-TTC) is one of the many benefits of being at the Advanced Technology Research Facility (ATRF), according to Courtney Silverthorn, Ph.D. Being in one location “has increased the effectiveness of both informal communication and formal meetings. We have already brainstormed solutions for several issues in the hallway during an informal chat,” said Silverthorn, an SAIC-Frederick IP specialist.</p>
<p>The IP Office works closely with NCI-TTC on matters related to collaboration agreements, materials and technology transfer, and invention reporting and patents. With the offices now just a few steps away from each other instead of in different buildings, Silverthorn said, “We can easily walk IP-related documents, such as invention reports or an original copy of a Material Transfer Agreement, down the hall instead of sending them through interoffice mail.” This aspect alone can save up to four business days, she said.</p>
<p>The IP Office reports all inventions made by SAIC-Frederick scientists to NCI-TTC, which evaluates the invention and makes decisions on patenting and marketing, Silverthorn explained. They often co-negotiate agreements with NCI-TTC when an interaction involves scientists from both NCI and SAIC-Frederick or when a collaboration with the external research community is in development.</p>
<p>In addition to collaboration agreements, the IP Office helps develop beta-test agreements, “which allow us to evaluate new equipment or software and provide feedback to the company,” Silverthorn said.</p>
<h2><strong>In-Person Assistance Readily Available</strong></h2>
<p>The IP Office interacts regularly with scientists from the Advanced Technology Program because of the frequency for which the labs are sought out for collaborations, Silverthorn said. “Many of them are now located in the ATRF, which means they can stop by if they have a question about entering into a collaborative agreement, exchanging materials or information with another party, or reporting an invention. We can assist them more effectively in person rather than exchanging a series of e-mails.”</p>
<h2><strong>If You Are Not Sure, Ask</strong></h2>
<p>If you have any questions or are not sure which agreement is appropriate for your research situation, contact the NCI Technology Transfer Center office: </p>
<p><strong>Telephone: </strong>301-845-5465</p>
<p><strong>Website: </strong><a href="http://ttc.nci.nih.gov" style="color: rgb(7, 130, 193); " target="_blank">http://ttc.nci.nih.gov</a></p>
<p><strong>Follow Us on Twitter</strong><br /><a href="http://twitter.com/NCITechTransfer" style="color: rgb(7, 130, 193); " target="_blank">http://twitter.com/NCITechTransfer</a></p>
<p><strong>Join our LinkedIn Group</strong><br /><a href="http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about" style="color: rgb(7, 130, 193); " target="_blank">http://www.linkedin.com/groups/NCITechTransfer-NCI-Technology-Transfer-Network-4688463/about</a></p>
</div></div></div><section class="field field-name-field-tags field-type-taxonomy-term-reference field-label-above view-mode-rss"><h2 class="field-label">Tags:&nbsp;</h2><ul class="field-items"><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/2012-september" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">2012 September</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/atrf" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">ATRF</a></li><li class="field-item even" rel="dc:subject"><a href="/about/theposter/tags/technology-transfer" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Technology Transfer</a></li><li class="field-item odd" rel="dc:subject"><a href="/about/theposter/tags/intellectual-property" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">Intellectual Property</a></li></ul></section>Tue, 11 Sep 2012 13:00:00 +0000schroyert50 at http://ncifrederick.cancer.gov/about/theposterhttp://ncifrederick.cancer.gov/about/theposter/content/new-location-improves-efficiency#comments